Your browser doesn't support javascript.
loading
Outcomes of kidney retransplantation in recipients with prior posttransplant lymphoproliferative disorders: An analysis of the 2000-2019 UNOS/OPTN database.
Leeaphorn, Napat; Thongprayoon, Charat; Chewcharat, Api; Hansrivijit, Panupong; Jadlowiec, Caroline C; Cummings, Lee S; Katari, Sreelatha; Mao, Shennen A; Mao, Michael A; Cheungpasitporn, Wisit.
Afiliación
  • Leeaphorn N; Renal Transplant Program, University of Missouri-Kansas City School of Medicine/Saint Luke's Health System, Kansas City, Missouri.
  • Thongprayoon C; Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
  • Chewcharat A; Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
  • Hansrivijit P; Department of Internal Medicine, University of Pittsburgh Medical Center Pinnacle, Harrisburg, Pennsylvania.
  • Jadlowiec CC; Division of Transplant Surgery, Mayo Clinic, Phoenix, Arizona.
  • Cummings LS; Renal Transplant Program, University of Missouri-Kansas City School of Medicine/Saint Luke's Health System, Kansas City, Missouri.
  • Katari S; Renal Transplant Program, University of Missouri-Kansas City School of Medicine/Saint Luke's Health System, Kansas City, Missouri.
  • Mao SA; Division of Transplant Surgery, Mayo Clinic, Jacksonville, Florida.
  • Mao MA; Division of Nephrology and Hypertension, Mayo Clinic, Jacksonville, Florida.
  • Cheungpasitporn W; Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
Am J Transplant ; 21(2): 846-853, 2021 02.
Article en En | MEDLINE | ID: mdl-33128832
ABSTRACT
This study utilized the UNOS database to assess clinical outcomes after kidney retransplantation in patients with a history of posttransplant lymphoproliferative disease (PTLD). Among second kidney transplant patients from 2000 to 2019, 254 had history of PTLD in their first kidney transplant, whereas 28,113 did not. After a second kidney transplant, PTLD occurred in 2.8% and 0.8% of patients with and without history of PTLD, respectively (p = .001). Over a median follow-up time of 4.5 years after a second kidney transplant, 5-year death-censored graft failure was 9.5% vs. 12.6% (p = .21), all-cause mortality was 8.3% vs. 11.8% (p = .51), and 1-year acute rejection was 11.0% vs. 9.3% (p = .36) in the PTLD vs. non-PTLD groups, respectively. There was no significant difference in death-censored graft failure, mortality, and acute rejection between PTLD and non-PTLD groups in adjusted analysis and after propensity score matching. We conclude that graft survival, patient survival, and acute rejection after kidney retransplantation are comparable between patients with and without history of PTLD, but PTLD occurrence after kidney retransplantation remains higher in patients with history of PTLD.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Asunto principal: Trasplante de Riñón / Trastornos Linfoproliferativos Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Am J Transplant Asunto de la revista: TRANSPLANTE Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Asunto principal: Trasplante de Riñón / Trastornos Linfoproliferativos Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Am J Transplant Asunto de la revista: TRANSPLANTE Año: 2021 Tipo del documento: Article